Atherosclerosis

Test Author ,

Morihiro Matsuda , Koji Hasegawa ,

Charles Amir German , Michael D Shapiro ,

Joost Daemen , Maria Natalia Tovar Forero ,

Tanush Gupta , Michael Weinreich , Mark Greenberg , et al

Alberto Lorenzatti , Peter P Toth ,

J Dopheide , J Veit , H Ramadani , et al

M Panajatovic , F Singh , U Duthaler , et al

GM Sanvee , M Panajatovic , J Bouitbir , et al

Edward T Carreras , Donna M Polk ,

Hans-Willi Breuer ,

Read time: 1h 1m 1s

Cameron T Lambert , Pratik Sandesara , Ijeoma Isiadinso , et al

Reynaria N Pitts , Robert H Eckel ,

Kerry Layne , Albert Ferro ,

Donald E Cutlip ,

Kazeen Abdullah , Anand Rohatgi ,

Yohei Sotomi , Richard A Shlofmitz , Antonio Colombo , et al

Iana Simova ,

Heather Currie , Christine Williams ,

Sven M Francque ,

Ewa Dembowski , Michael H Davidson ,

About

Substantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.

Articles